Spots Global Cancer Trial Database for duvelisib
Every month we try and update this database with for duvelisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | NCT05044039 | Non-hodgkin Lym... Acute Lymphocyt... | Duvelisib | 18 Years - | Washington University School of Medicine | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma | NCT04038359 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03372057 | Peripheral T-ce... | Duvelisib Duvelisib Duvelisib | 18 Years - | SecuraBio | |
| Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | NCT04688658 | Unresectable Me... | Nivolumab Duvelisib | 18 Years - | University of Pittsburgh | |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | NCT04803201 | Angioimmunoblas... Enteropathy-Ass... Follicular T-Ce... Mature T-Cell a... Monomorphic Epi... Nodal Periphera... Peripheral T-Ce... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Etoposide Duvelisib Oral azacitidin... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | NCT02391545 | CD20+ Follicula... | Duvelisib Rituximab Obinutuzumab | 18 Years - | SecuraBio | |
| A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03372057 | Peripheral T-ce... | Duvelisib Duvelisib Duvelisib | 18 Years - | SecuraBio | |
| Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | NCT04688658 | Unresectable Me... | Nivolumab Duvelisib | 18 Years - | University of Pittsburgh | |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma | NCT05010005 | T-cell Lymphoma... NK-Cell Lymphom... T-cell Prolymph... T-cell Large Gr... | Ruxolitinib Duvelisib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | NCT02605694 | Lymphoma | Duvelisib Rituximab R-CHOP Prednisone | 18 Years - | SecuraBio | |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | NCT04342117 | Lymphoma, Small... Lymphoma Lymphoma, Non-H... Chronic Lymphoc... Follicular Lymp... | duvelisib PI3K inhibitor | 18 Years - | SecuraBio | |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | NCT04803201 | Angioimmunoblas... Enteropathy-Ass... Follicular T-Ce... Mature T-Cell a... Monomorphic Epi... Nodal Periphera... Peripheral T-Ce... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Etoposide Duvelisib Oral azacitidin... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | NCT04803201 | Angioimmunoblas... Enteropathy-Ass... Follicular T-Ce... Mature T-Cell a... Monomorphic Epi... Nodal Periphera... Peripheral T-Ce... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Etoposide Duvelisib Oral azacitidin... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | NCT04193293 | Head and Neck S... | Duvelisib Pembrolizumab | 18 Years - | SecuraBio | |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | NCT04890236 | Recurrent Diffu... Refractory Diff... | Duvelisib Tisagenlecleuce... | 18 Years - | Emory University | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) | NCT05976997 | Newly Diagnosed... | Duvelisib, Chid... | 18 Years - 70 Years | Huazhong University of Science and Technology | |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | NCT04652960 | Stage IIB Mycos... Stage III Mycos... Stage IV Mycosi... | Biospecimen Col... Computed Tomogr... Duvelisib Nivolumab Positron Emissi... Punch Biopsy | 18 Years - | National Cancer Institute (NCI) | |
| A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma | NCT04707079 | Follicular Lymp... | Duvelisib | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma | NCT01882803 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma | NCT01882803 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | NCT04890236 | Recurrent Diffu... Refractory Diff... | Duvelisib Tisagenlecleuce... | 18 Years - | Emory University | |
| Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | NCT02598570 | Lymphoma | duvelisib | 20 Years - 99 Years | AbbVie | |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT03961672 | Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... | Duvelisib | 18 Years - | City of Hope Medical Center | |
| Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | NCT03370185 | Chronic Lymphoc... Small Lymphocyt... | Duvelisib | 18 Years - | SecuraBio | |
| Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT04209621 | Small Lymphocyt... Chronic Lymphoc... | Duvelisib Ibrutinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors | NCT05508659 | Advanced Solid ... | Duvelisib SG001 | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | NCT05057247 | Squamous Cell C... Recurrent Squam... Metastatic Head... Advanced Head a... Advanced Head a... | Duvelisib Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | NCT03370185 | Chronic Lymphoc... Small Lymphocyt... | Duvelisib | 18 Years - | SecuraBio | |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT03961672 | Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... | Duvelisib | 18 Years - | City of Hope Medical Center | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma | NCT02204982 | Follicular Lymp... | Duvelisib Placebo Rituximab | 18 Years - | SecuraBio | |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | NCT05065866 | Non Hodgkin Lym... Hodgkin Lymphom... Myeloma Lymphocytic Leu... | BMS-986345 Duvelisib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma | NCT04038359 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) | NCT02711852 | Hematologic Mal... | Duvelisib | 18 Years - | SecuraBio | |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | NCT03892044 | Chronic Lymphoc... Recurrent Diffu... Refractory Diff... Richter Syndrom... Small Lymphocyt... Transformed Chr... Transformed Fol... Transformed Sma... | Duvelisib Nivolumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | NCT02598570 | Lymphoma | duvelisib | 20 Years - 99 Years | AbbVie | |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | NCT03892044 | Chronic Lymphoc... Recurrent Diffu... Refractory Diff... Richter Syndrom... Small Lymphocyt... Transformed Chr... Transformed Fol... Transformed Sma... | Duvelisib Nivolumab | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
